Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation-Positive Malignancies
A first‑in‑human, open‑label Phase 1/2 study evaluates the safety, tolerability and dosing of S241656 monotherapy and in combination with other anti‑cancer therapies in adults with advanced or metastatic solid tumours harbouring RAS or RAF mutations, including KRAS, HRAS, NRAS, BRAF and RAF1.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT